While the involvement of the IL-1 cytokines and their counterplayers in the development, progression and metastasis of cancer has been described in preclinical models for decades, it was not until 2015 that Ridker et al. were able to provide more solid evidence in a clinical setting. Here, IL1B is linked to cancer.